Cereno Scientific

“I am very happy about the prospect of welcoming Jeppe Øvlesen to the board of Cereno. He has a wealth of experience from executive positions in the Nordic biotech industry. I especially believe his expertise in merger and acquisition (M&A) and business development (BD) will play a key part in the time ahead. As we gear up, following the exciting findings from the data quality control review in the Phase II study of CS1 that was reported last week, focus on M&A and BD will get into full swing,” said Joakim Söderström, Chairman of Cereno Scientific.

Jeppe Øvlesen, born 1962, has an MBA with a focus on leadership and finance from the University of Hartford, US. Øvlesen has experience in business development and has been involved in more than 20 successful start-ups in medtech, biotech, and IT, including CLC Bio, Cetrea and Monsenso. Øvlesen has previously been CEO at SynAct Pharma AB (publ), ChemoMetec A/S and PNN Medical A/S. Previous experience also includes founding TXP Pharma, and holding executive positions as CFO and Vice President of business development at Action Pharma A/S, whose lead candidate was sold to AbbVie for 110 MUSD. Jeppe is currently chairman in HG Energy Group A/S, Cercare Medical A/S, Go-Pen A/S, and Neurescue ApS, and is a board member in Perfusion Tech Aps, and ResoTher Pharma Aps.

“I very much look forward to contributing to Cereno’s continued success. Cereno has a broad and very promising cardiovascular drug development portfolio, an experienced team, and is supported by highly renowned thought leaders in the cardiovascular disease space – which uniquely positions the company. I believe I am joining at a thrilling time for the company,” said Jeppe Øvlesen, proposed board member of Cereno Scientific.

For further information, please contact:

Eva Jagenheim, CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.